NASDAQ: POMPomdoctor Ltd Stock
$4.30+0.02 (+0.47%)
Updated Oct 21, 2025
POM Price
$4.30
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$3.47
52 Week High
$5.04
P/E
-8.08x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$48.11M
Earnings
-$5.12M
Gross Margin
13.9%
Operating Margin
-7.12%
Profit Margin
-41.9%
Debt to Equity
-0.24
Operating Cash Flow
-$2M
Beta
1.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
POM Overview
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine POM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
POM
Ranked#2 of 4
Ranked#2 of 4
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.32 | B | |
| $0.52 | D | |
| $2.65 | D |
Be the first to know about important POM news, forecast changes, insider trades & much more!
POM News
Overview
Due Diligence Score
–
Industry Average (21)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how POM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
POM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
POM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
POM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more POM due diligence checks available for Premium users.
Valuation
POM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.08x
Industry
-32.17x
Market
38.14x
POM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
POM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
POM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.3M
Liabilities
$74.8M
Debt to equity
-0.24
POM's short-term liabilities ($25.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
POM's long-term liabilities ($51.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
POM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
POM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
POM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
POM vs Pharmaceutical Retailer Stocks
Pomdoctor Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.